Organization · Venture Capital
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm based in Paris, specializing in life sciences investments across the entire value chain. With over €4 billion in assets under management, the firm has supported more than 500 companies since its founding in 1972.
Overview
What Sofinnova Partners does
What Sofinnova Partners is
Sofinnova Partners is a leading European venture capital firm based in Paris, specializing in life sciences investments across the entire value chain. With over €4 billion in assets under management, the firm has supported more than 500 companies since its founding in 1972.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 1972
- Approximate age
- About 54 years
- Structured capabilities
- Funder
- Last reviewed
- April 23, 2026
Official channels
Find Sofinnova Partners elsewhere
Open the official website or a supported primary organization account.
Capability profile
Sofinnova Partners as a funder
Investment thesis
Sofinnova Partners focuses exclusively on life sciences, investing across the entire value chain from seed to growth stages. The firm emphasizes biopharma, medtech, industrial biotech, and digital medicine, leveraging deep clinical and regulatory expertise to support portfolio companies.
Focus narrative
Sofinnova Partners invests across the entire value chain of life sciences, focusing on biopharma, medtech, digital medicine, agriculture, and industrial processes. Their investment strategies include early-stage biopharma and medtech start-ups, an in-house medtech accelerator, and growth-stage biotech and medtech companies, among others.
Value beyond capital
Sofinnova Partners adds value to its portfolio companies through deep clinical and regulatory expertise, hands-on support throughout milestones, and access to a strong transatlantic syndicate. The firm is committed to nurturing innovation and facilitating growth in the life sciences sector.
Terms and economics
- Typical check
- $1,000,000–$750,000,000
- Sweet spot
- $10,000,000
Focus and fit
- Stages
- Seed · Series A · Series B · Growth Equity
- Regions
- Global · Europe
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 151
Portfolio context
Notable portfolio companies include: Afyren: Focuses on sustainable bioprocesses. Abivax: Develops therapies for inflammatory diseases. Betteromics: Works at the intersection of digital medicine and biotechnology. CorWave: Develops innovative heart failure therapies. May Health: Advances technology for treating PCOS-related infertility. Elevara Medicines: Involved in clinical trials for rheumatoid arthritis treatments.
Common questions
What to know about Sofinnova Partners
Upseed classifies Sofinnova Partners under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 23, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.